Coya Therapeutics appoints Arun Swaminathan as CEO, Howard Berman becomes Executive Chairman effective Nov 1, 2024

Coya Therapeutics, Inc.

Swaminathan employment agreement provides $525,000 base salary, eligible for annual bonus up to 50% of base.
Berman employment agreement provides $420,000 base salary, eligible for annual bonus up to 50% of base.
Swaminathan becomes CEO on Nov 1, 2024; Berman resigns as CEO on Oct 31, 2024, remains on Board as Executive Chairman.
Severance: if terminated without cause, 12 months base salary continuation plus prorated bonus for each.
Non-compete for Swaminathan: 6 months post-termination, restricted to IL-2, CTLA-4 Ig, exosome product companies.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Howard Berman

Executive Chairman

COYA · Coya Therapeutics, Inc.

Effective: 2024-10-31
Successor: Arun Swaminathan
Filed: October 31, 2024, 7:59 PM ET

The Berman Employment Agreement provides for Dr. Berman to serve as Executive Chairman and provides for an annual base salary of $420,000.

Appointed

Arun Swaminathan

Chief Executive Officer

COYA · Coya Therapeutics, Inc.

Effective: 2024-11-01
Filed: October 31, 2024, 7:59 PM ET

Dr. Swaminathan was appointed as the Company’s Chief Executive Officer, effective November 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Howard Berman was appointed as Executive Chairman at Coya Therapeutics, Inc..

Action: resigned as Chief Executive Officer and appointed as Executive Chairman
Role: Executive Chairman

Exact text from the filing

The Berman Employment Agreement provides for Dr. Berman to serve as Executive Chairman and provides for an annual base salary of $420,000.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Arun Swaminathan was appointed as Chief Executive Officer at Coya Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Dr. Swaminathan was appointed as the Company’s Chief Executive Officer, effective November 1, 2024.

View on SEC.gov

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-248755

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.